// App-Quantinova.ai

566 : BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy

Researchers

Presenter

  • Gro Gausdal

Principal Investigators

  • Kjersti Davidsen

  • Katarzyna Wnuk-Lipinska

  • Kathleen Wiertel

  • Jing Kang

  • Agnete Engelsen

  • Sebastien Bougnaud

  • Monica Hellesy

  • Magnus Bl

  • Lavina Ahmed

  • Linn Hodneland

  • Sergej Kiprijanov

  • Oddbjrn Straume

  • Rolf A. Brekken

  • James B. Lorens

Medical Centers

  • BergenBio AS, Bergen, Norway

  • Department of Biomedicine, Center for Cancer Biomarkers, University of Bergen, Bergen, Norway

  • Division of Surgical Oncology Department of Surgery, Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX

  • Department of Oncology, Haukeland University Hospital, Bergen, Norway

Locations

  • United States

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • AXL receptor tyrosine kinase

  • Hepatocyte growth factor receptor

  • Solute Carrier Family 22 Member 3

Drug/Treatment

  • L-Tyrosine

  • BGB-324

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved